| Literature DB >> 34200665 |
Gustavo Ignacio Vazquez-Cervantes1, Daniela Ramírez Ortega1, Tonali Blanco Ayala1, Verónica Pérez de la Cruz1, Dinora Fabiola González Esquivel1, Aleli Salazar2, Benjamín Pineda2.
Abstract
Beer is a fermented beverage widely consumed worldwide with high nutritional and biological value due to its bioactive components. It has been described that both alcoholic and non-alcoholic beer have several nutrients derived from their ingredients including vitamins, minerals, proteins, carbohydrates, and antioxidants that make beer a potential functional supplement. Some of these compounds possess redox, anti-inflammatory and anticarcinogenic properties making the benefits of moderate beer consumption an attractive way to improve human health. Specifically, the hop cones used for beer brewing provide essential oils, bitter acids and flavonoids that are potent antioxidants and immune response modulators. This review focuses on the redox and anti-inflammatory properties of hop derivatives and summarizes the current knowledge of their neuroprotective effects.Entities:
Keywords: antioxidant; beer; hop; prenylflavonoids; xanthohumol
Year: 2021 PMID: 34200665 PMCID: PMC8226943 DOI: 10.3390/nu13062000
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1The main derived compounds from hop cones. Hop cones are the main source of bioactive compounds during the brewing process. Hops contribute essential oils, phenolic compounds such as flavonoids which can be further classified into flavonols, chalcones, and flavones. Hop cones contain α-acids and β-acids also known as bitter acids.
Figure 2Cellular mechanisms of the anti-inflammatory, immunomodulatory and antioxidant effects exerted by hop compounds. Polyphenols extracted from H. lupulus such as xanthohumol, isoxanthohumol and bitter acids can interfere with intracellular immune signaling pathways at different levels. Due to the inhibition of TLR4 activation through preventing the association of TLR4 dimers with the co-stimulatory molecule MD2, NF-κB nuclear translocation was prevented. Hop compounds inhibit NF-κB signaling pathway due to both, the inhibition of TLR4 activation through preventing the association of TLR4 dimers with the co-stimulatory molecule MD2, and in a TLR-independent fashion. Hop compounds can inhibit other pro-inflammatory signaling pathways driven by STAT-1 and IRF-1. Thus, reducing the expression of the subset of pro-inflammatory mediators such as IL-1β, IL-6, IL-8, IL-10, IL-12, TNF-α, inflammasome subunits, nitric oxide, cyclooxygenases, and prostaglandin production, adhesion molecules such as ICAM-1, MCP-1, and MIP-1. Simultaneously, hop compounds promote microglial phagocytic activity together with the switching to M2 phenotype. In different cell types, hop compounds also prevent fibrotic processes by reducing the expression of α-SMA or TGF-β. However, hop compounds also promote the pro-inflammatory and cytotoxic responses from lymphocytes to elicit anti-tumor responses. Finally, in many cases, the anti-inflammatory effects of hop compounds are accompanied by the activation of the antioxidant response regulator, Nrf-2, and the increase in the production of HO-1, NQO-1, GST, GCL, Trx-1 and TrxR-1.
Effects of beer compounds on immunomodulation.
| Beer Compound | In Vitro/In Vivo/Clinical Study | Effect | References |
|---|---|---|---|
|
| In vitro | ||
| Monocytes/macrophages |
Decreased expression of TLR-4. Interference with TLR-4/MD-2 association. Inhibition of NF-κB signaling. Decreased expression of inflammasome subunits. Decreased production of IL-1β, IL-6, IL-12, MCP-1, TNF-α, and NO. | [ | |
| Dendritic cells |
Increased formation of ceramide. Activation of caspase-8-mediated apoptosis. | [ | |
| T lymphocytes |
Antiproliferative. Increased apoptosis. Reduced lymphocyte cytotoxic activity. Inhibition of JAK/STAT and NF-ΚB signaling. Decreased production of IL-2, TNF-α and IFN-γ. | [ | |
| Mice primary chondrocytes. |
Inhibition of NF-κB signaling. Reduced production of TNF-α, IL-8, PGE-2 and NO. | [ | |
| IEC-6 intestinal epithelium |
Inhibition of NF-κB signaling. | [ | |
| Primary hepatocytes and hepatic stellate cells (5–10 µM). |
Inhibition of NF-κB signaling. Decreased production of IL-8 and MCP-1. | [ | |
| HUVEC cells |
-Inhibited capillary-like structure formation. | [ | |
| In vivo | |||
| Mice, dextran sodium sulfate-induced colitis (0.1–10 mg/kg orally). |
Inhibition of NF-κB signaling. Decreased levels of IL-1β, TNF-α and COX2. | [ | |
| Liver inflammation, |
Inhibition of NF-κB signaling. Decreased levels of IL-1α, IL-6, MCP-1, TNF-α and ICAM-1. Decreased levels of TGF-β, α-SMA and collagen. | [ | |
| Oxalazone-induced inflammation |
Reduction in ear thickness. | [ | |
| LPS-induced lung injury (10–50 mg/kg intraperitoneally). |
Reduced neutrophil count and MPO activity. Decreased expression of inflammasome subunits. Reduced levels of IL-1β, IL-6, TNF-α and NO. | [ | |
| Skin wound healing |
Decreased levels of IL-1β, NO and VEGF. Decreased angiogenesis. | [ | |
| High-fat diet-induced inflammation (0.01%). |
Reduced levels of circulating IL-1β and TNF-α. | [ | |
| Mice, breast cancer |
Increased levels of IL-2 and IFN-γ. Lymphocyte polarization towards TH1 phenotype. Increased anti-tumor lymphocyte activity. Reduced tumor volume. | [ | |
|
| In vitro | ||
| RAW 264.7 macrophages |
Inhibition of NF-κB activation. Decreased expression of TNF-α, iNOS, COX1 and COX2. | [ | |
| HUVEC cells |
Decreased expression of COX2. Decreased PGI-2 production. Promoted capillary-like structure formation. | [ | |
| Spleenic adherent cells |
Decreased production of IL-12. | [ | |
| In vivo | |||
| Rat skin wound healing |
Increased level of IL-1β. Increased angiogenesis. | [ | |
|
| In vitro | ||
| Primary hepatocytes and hepatic stellate cells |
Decreased production of IL-8, ICAM-1, TGF-β and α-SMA. Increased proliferation. | [ | |
| BV-2 microglial cells |
Decreased production of NO on LPS-stimulated cells. | [ | |
| Mice primary microglia culture. |
Increased amyloid-β phagocytosis. Decreased production of TNF-α IL-1β, IL-6, IL-10, IL-12, MIP-1 and MCP-1. | [ | |
| In vivo | |||
| Western diet-induced non-alcoholic liver disease mice. |
Decreased levels of IL-1α and TNF-α. Reduced expression of adhesion molecules. Decreased levels of TGF-β, MMP-1 and α-SMA. Decreased lymphocyte infiltration into the liver. | [ | |
| Rat intracerebral hemorrhage. |
Microglial polarization towards M2 phenotype. Decreased NF-κB expression. Reduced levels of IL-1β and TNF-α. | [ | |
| 5xFAD mice (Alzheimer’s experimental model) |
Microglial polarization towards M2 phenotype. Increased phagocytic activity. Decreased soluble amyloid-β. Prevention of amyloid-β deposition. Decreased production of IL-1β, IL-12 and MIP-1α. Amelioration of cognitive impairment. | [ | |
| rTg4510 mice (tauopathy experimental model) |
Reduced levels of IL-1β, IL-12, TNF-α and MIP-1. Decreased levels of phosphorylated tau. | [ | |
| Aged mice. |
Microglial polarization towards M2 phenotype. Reduced levels of TNF-α and IL-1β. Reduced level of amyloid-β and glutamate. Increased level of dopamine. Improved age-related cognitive impairment. | [ | |
|
| In vivo | ||
| TPA-induced skin inflammation in mice (5–50 µg/mL topically). |
Inhibition of NF-ΚB signaling. Decreased pro-inflammatory markers iNOS, COX1 and COX2. Decreased infiltrated lymphocytes in the skin. Prevention of tumor formation. | [ | |
|
| In vitro | ||
| Hepatic stellate cells |
Decreased activation of NF-κB signaling. Reduced production of MCP-1 and RANTES. Decreased α-SMA expression. | [ | |
| L929sA fibroblasts |
Reduced NF-κB activation. Reduced IL-6 production. | [ | |
| In vivo | |||
| Vagotomized and LPS-intoxicated mice (1–50 mg/kg). |
Reduced blood levels of IL-1β. Prevention of dendritic spine loss. Improved depression-like behavior. | [ | |
|
| In vitro | ||
| RAW 264.7 macrophages |
Decreased production of IL-1β, IL-6, TNF-α, MCP-1 and NO. | [ | |
| THP-1 myeloid cells (0.1–2%). |
Decreased production of IL-10 and TNF-α. Inhibition of NF-κB activation. | [ | |
| PBMCs (3.6–30 µg/mL). |
Decreased COX-2 activity and PGE-2 production. | [ | |
| Human nasal epithelial cells (0.1–50 µg/mL). |
Decreased TSLP and TNF-α production. | [ | |
|
| In vivo | ||
| 42 mL beer/kg body weight. |
Decreased expression of ICAM, VCAM, NF-κB. Prevention of atherosclerotic plaque formation. | [ | |
| Drinkable beer ad libitum. |
Increased number of anti-tumor reactive lymphocytes. No difference in tumor growth. | [ | |
| Clinical study on healthy subjects | |||
| Alcoholic beer |
Prevented radiation-induced lymphocyte DNA damage (ex vivo). Reduced lymphocyte cytotoxic activity. | [ | |
| Long term. | |||
| Alcoholic beer |
No changes in cell adhesion molecules. Increased number of circulating lymphocytes (women). Increased serum levels of IgM, IgA and IgG. Increased monocyte oxidative burst capacity (ex vivo). Increased cytokine production capacity (ex vivo). | [ | |
| Non-alcoholic beer |
Unchanged levels of complement system molecules. Decreased the acute rise of IL-6 and leukocyte after endurance aerobic exercise. | [ | |
| Clinical study on cardiovascular risk subjects. | |||
| Alcoholic beer |
Increased level of macrophage microRNA: miR-145a-5p. Decreased levels of lymphocyte adhesion molecules and IL-5. Increased levels of IL-1 receptor antagonist. | [ | |
| Non-alcoholic beer |
Decreased level of macrophage microRNAs: miR-320a-3p, miR-92a-5p, miR-20a-5p and miR-17- 5p. Decreased level of monocyte and lymphocyte adhesion molecules. Decreased level of IL-6r, IL-15 and RANTES. | [ | |
Figure 3Mechanisms of neuroprotection by prenylflavonoids. It has been described that prenyl flavonoids such as xanthohumol can modulate the GABAA receptors, thus increasing intracellular Cl− concentrations and reducing Ca2+ influx, leading to a decrease in glutamate release, and preventing an exacerbated excitotoxic neuronal damage. Additionally, hop metabolites can modulate the redox environment through Nrf2 signaling, regulating the expression of mitochondrial proteins, or preventing oxidative damage by directly scavenging ROS.